AbbVie Revenue Rises 8.6% to $61.2B; Secures $1.925B ISB 2001 Licensing Deal
ABBV•ABBV•ABBV•ABBV•AbbVie posted $61.2B in revenue, up 8.6% year-over-year, driven by new product launches that offset Humira declines, while Pfizer’s revenue slipped 1.6% to $62.6B. AbbVie secured licensing rights to ISB 2001 in a deal with Glenmark worth up to $1.925B, strengthening its late-stage pipeline.
AbbVie reported $61.2B in annual revenue, up 8.6% year-over-year, fueled by strong uptake of recent product launches. In contrast, Pfizer’s revenue declined 1.6% to $62.6B, highlighting AbbVie’s superior growth momentum in the sector.
Continued Humira patent expirations led to lower biologics sales, but AbbVie offset these losses with robust performance from immunology drugs such as Skyrizi and Rinvoq, which expanded into new markets and indications.
AbbVie secured exclusive rights to Glenmark’s ISB 2001 for up to $1.925B, adding a late-stage oncology asset to its pipeline and diversifying its R&D portfolio beyond immunology.
